Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Venetoclax Combined With Azacitidine”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)WithdrawnNCT04973618
What this trial is testing

Study of APVO436 in Elderly or Unfit Patients With Newly Diagnosed AML

Who this might be right for
AML
Aptevo Therapeutics
Testing effectiveness (Phase 2)Ended earlyNCT04905407
What this trial is testing

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Who this might be right for
Acute Myeloid Leukemia
Syros Pharmaceuticals 66
Testing effectiveness (Phase 2)Active Not RecruitingNCT05833438
What this trial is testing

Venetoclax in Combination With 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy

Who this might be right for
Acute Myeloid Leukemia (AML)
University of Leipzig 45
Testing effectiveness (Phase 2)Looking for participantsNCT07047183
What this trial is testing

Clinical Study of Venetoclax Combined With Azacitidine as Bridging Therapy Prior to Hematopoietic Stem Cell Transplantation in Patients With Higher-Risk Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic NeoplasmsTransplantation
Yehui Tan 46
Testing effectiveness (Phase 2)Looking for participantsNCT04588922
What this trial is testing

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Who this might be right for
Hematologic Malignancies
Sellas Life Sciences Group 160
Early research (Phase 1)Looking for participantsNCT06634394
What this trial is testing

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

Who this might be right for
Acute Myeloid Leukemia (AML)
Aptevo Therapeutics 39
Testing effectiveness (Phase 2)Looking for participantsNCT06394011
What this trial is testing

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Who this might be right for
Intermediate Risk Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia
The First Affiliated Hospital of Soochow University 60
Testing effectiveness (Phase 2)Active Not RecruitingNCT04284787
What this trial is testing

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia Post Cytotoxic Therapy+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06451861
What this trial is testing

Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

Who this might be right for
Acute Myeloid Leukemia
Guangdong Provincial People's Hospital 240
Testing effectiveness (Phase 2)Ended earlyNCT04150029
What this trial is testing

MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy

Who this might be right for
Acute Myeloid Leukemia
Novartis Pharmaceuticals 90
Testing effectiveness (Phase 2)Ended earlyNCT04160052
What this trial is testing

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Who this might be right for
Chronic Myelomonocytic LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+2 more
M.D. Anderson Cancer Center 51
Large-scale testing (Phase 3)Ended earlyNCT05079230
What this trial is testing

Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gilead Sciences 378
Early research (Phase 1)Looking for participantsNCT06419634
What this trial is testing

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Bristol-Myers Squibb 105
Large-scale testing (Phase 3)Not Yet RecruitingNCT07082452
What this trial is testing

Trial Evaluating Efficacy and Safety of A Reduced Venetoclax Exposure To Seven Days Versus Standard Continuous Venetoclax Exposure Combined With Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Intensive Induction

Who this might be right for
Leukemia, B-Cell, ChronicLeukemia
Gustave Roussy, Cancer Campus, Grand Paris 262
Testing effectiveness (Phase 2)Ended earlyNCT04812548
What this trial is testing

Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants

Who this might be right for
Myelodysplastic Syndrome (MDS)
Novartis Pharmaceuticals 20
Testing effectiveness (Phase 2)Looking for participantsNCT06548230
What this trial is testing

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

Who this might be right for
Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)
M.D. Anderson Cancer Center 40
Large-scale testing (Phase 3)Looking for participantsNCT07007312
What this trial is testing

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Who this might be right for
Acute Myeloid Leukemia (AML)
Kura Oncology, Inc. 1,300
Early research (Phase 1)Ended earlyNCT05107856
What this trial is testing

PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

Who this might be right for
Acute Myeloid LeukemiaB-cell Non-Hodgkin LymphomaChronic Lymphocytic Leukemia+7 more
Prelude Therapeutics Incorporated 21
Early research (Phase 1)Temporarily pausedNCT06454409
What this trial is testing

Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Myelodysplastic Syndrome/Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Myelodysplastic Syndrome+2 more
City of Hope Medical Center 20
Testing effectiveness (Phase 2)Study completedNCT04687761
What this trial is testing

Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old

Who this might be right for
Leukemia, Myeloid, AcuteDe NovoAge More 60yr
PETHEMA Foundation 113
Next Page
60